CO2023006731A2 - Composiciones y métodos para el tratamiento de la celiaquía - Google Patents

Composiciones y métodos para el tratamiento de la celiaquía

Info

Publication number
CO2023006731A2
CO2023006731A2 CONC2023/0006731A CO2023006731A CO2023006731A2 CO 2023006731 A2 CO2023006731 A2 CO 2023006731A2 CO 2023006731 A CO2023006731 A CO 2023006731A CO 2023006731 A2 CO2023006731 A2 CO 2023006731A2
Authority
CO
Colombia
Prior art keywords
methods
celiac disease
compositions
treatment
celiac
Prior art date
Application number
CONC2023/0006731A
Other languages
English (en)
Spanish (es)
Inventor
David Baker
Lance Stewart
Ingrid Swanson Pultz
Clancey Wolf
Justin Bloomfield Siegel
Christine Elaine Tinberg
Original Assignee
Univ California
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Univ Washington filed Critical Univ California
Publication of CO2023006731A2 publication Critical patent/CO2023006731A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2023/0006731A 2020-10-30 2023-05-24 Composiciones y métodos para el tratamiento de la celiaquía CO2023006731A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108163P 2020-10-30 2020-10-30
PCT/US2021/057197 WO2022094177A1 (en) 2020-10-30 2021-10-29 Compositions and methods for treating celiac sprue disease

Publications (1)

Publication Number Publication Date
CO2023006731A2 true CO2023006731A2 (es) 2023-06-09

Family

ID=78819631

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006731A CO2023006731A2 (es) 2020-10-30 2023-05-24 Composiciones y métodos para el tratamiento de la celiaquía

Country Status (12)

Country Link
US (1) US20250064903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237554A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548083A (cg-RX-API-DMAC7.html)
KR (1) KR20230093323A (cg-RX-API-DMAC7.html)
CN (1) CN116829166A (cg-RX-API-DMAC7.html)
AR (1) AR123961A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021368118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195929A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006731A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023004807A (cg-RX-API-DMAC7.html)
TW (1) TW202233834A (cg-RX-API-DMAC7.html)
WO (1) WO2022094177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE440857T1 (de) * 1998-10-05 2009-09-15 Takeda Pharmaceutical Verfahren zum eliminieren von n-terminalem methionin
JP4475707B2 (ja) * 1998-10-05 2010-06-09 武田薬品工業株式会社 N末端メチオニンの除去方法
LT2718434T (lt) 2011-08-10 2018-08-10 University Of Washington Through Its Center For Commercialization Kompozicijos ir būdai, skirti celiakijos gydymui
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
ES2883347T3 (es) * 2014-06-16 2021-12-07 Codexis Inc Composiciones y procedimientos para atenuar y prevenir la inflamación intestinal debida a la presencia de antígenos alimentarios peptídicos en un intestino
TN2017000520A1 (en) * 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
MX2019007287A (es) * 2016-12-22 2019-09-27 Ew Nutrition Gmbh Variantes de proteasas estables.

Also Published As

Publication number Publication date
EP4237554A1 (en) 2023-09-06
AU2021368118A1 (en) 2023-05-11
CA3195929A1 (en) 2022-05-05
AR123961A1 (es) 2023-01-25
JP2023548083A (ja) 2023-11-15
KR20230093323A (ko) 2023-06-27
WO2022094177A1 (en) 2022-05-05
MX2023004807A (es) 2023-05-10
US20250064903A1 (en) 2025-02-27
TW202233834A (zh) 2022-09-01
AU2021368118A9 (en) 2023-07-06
CN116829166A (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
CL2024000410A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
MX2020009514A (es) Anticuerpos anti-claudina 18.2 (cldn18.2).
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
MX2021015753A (es) Constructo de arn.
CL2020001944A1 (es) Proteínas de fusión fc il-22 y métodos de uso.
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112019000015A2 (pt) distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
BR112018013071A2 (pt) uso de derivados de triptofano para formulações de proteínas
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
MX2020003095A (es) Arni variante.
ECSP22014455A (es) Anticuerpos anti-cd96 y sus métodos de uso
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
MX2021015501A (es) Anticuerpos y metodos de uso.
BR112018010669A8 (pt) anticorpo anti-pcsk9 e utilização do mesmo
CO2023016037A2 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
MX2019000235A (es) Eliminacion de la cistina mediada por enzimas humanas.
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
MX2023004807A (es) Composiciones y metodos para el tratamiento de la celiaquia.
CO2020013557A2 (es) Variantes de lfa3 y composiciones y usos de las mismas
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos